Edition:
United States

Rxi Pharmaceuticals Corp (RXII.OQ)

RXII.OQ on NASDAQ Stock Exchange Capital Market

1.84USD
4:00pm EDT
Change (% chg)

$-0.04 (-2.13%)
Prev Close
$1.88
Open
$1.86
Day's High
$1.88
Day's Low
$1.82
Volume
14,352
Avg. Vol
60,230
52-wk High
$7.60
52-wk Low
$1.78

Chart for

About

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company's development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.... (more)

Overall

Beta: 1.75
Market Cap(Mil.): $11.85
Shares Outstanding(Mil.): 23.25
Dividend: --
Yield (%): --

Financials

  RXII.OQ Industry Sector
P/E (TTM): -- 85.36 32.76
EPS (TTM): -1.32 -- --
ROI: -229.71 2.21 14.61
ROE: -267.77 3.85 16.34

BRIEF-Rxi Pharmaceuticals Announces Positive Results From Phase 2 Trial With Samcyprone For Treatment Of Common Warts

* RXI PHARMACEUTICALS ANNOUNCES POSITIVE RESULTS FROM PHASE 2 TRIAL WITH SAMCYPRONE™ FOR THE TREATMENT OF COMMON WARTS

May 18 2018

BRIEF-RXI Pharmaceuticals Says Selling Stockholders Are Offering On A Resale Basis An Aggregate Of 1.2 Million Shares Of Co's Common Stock

* RXI PHARMACEUTICALS CORP SAYS SELLING STOCKHOLDERS ARE OFFERING ON A RESALE BASIS AN AGGREGATE OF 1.2 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING Source text: (https://bit.ly/2IbzxKR) Further company coverage:

May 09 2018

BRIEF-RXi Pharmaceuticals Announces Grant Of Patent From USPTO For sd-rxRNAs To Treat Fibrotic Disorders

* RXI PHARMACEUTICALS - GRANTED PATENT FROM USPTO FOR METHODS OF USE OF SD-RXRNAS TARGETING CONNECTIVE TISSUE GROWTH FACTOR TO TREAT FIBROTIC DISORDERS Source text for Eikon: Further company coverage:

May 08 2018

BRIEF-Intracoastal Capital LLC Reports 9.2 Pct Passive Stake In RXI Pharmaceuticals Corp, As Of April 9

* INTRACOASTAL CAPITAL LLC REPORTS 9.2 PERCENT PASSIVE STAKE IN RXI PHARMACEUTICALS CORP, AS OF APRIL 9, 2018 - SEC FILING Source text: [https://bit.ly/2vwj7uq] Further company coverage:

Apr 18 2018

BRIEF-Lincoln Park Capital Reports 9.99 Pct Passive Stake In Rxi Pharmaceuticals

* LINCOLN PARK CAPITAL FUND, LLC REPORTS 9.99 PCT PASSIVE STAKE IN RXI PHARMACEUTICALS CORP AS OF APRIL 9, 2018 SEC FILING Source: (https://bit.ly/2HzQ63m) Further company coverage:

Apr 13 2018

BRIEF-Rxi Pharmaceuticals Announces Closing Of $4.9 Million Registered Direct Offering

* RXI PHARMACEUTICALS ANNOUNCES CLOSING OF $4.9 MILLION REGISTERED DIRECT OFFERING Source text for Eikon: Further company coverage:

Apr 11 2018

BRIEF-Rxi Pharmaceuticals Says $4.9 Mln Registered Direct Offering Priced At-The Market

* RXI PHARMACEUTICALS ANNOUNCES $4.9 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET

Apr 09 2018

BRIEF-Rxi Pharmaceuticals Files For Mixed Shelf Of Upto $100 Million

* RXI PHARMACEUTICALS CORP FILES FOR MIXED SHELF OF UPTO $100 MILLION - SEC FILING Source text: (https://bit.ly/2If6FB2) Further company coverage:

Mar 29 2018

BRIEF-RXI Says Determined Interim Financial Statements For Qtrs Ended March 31, June 30, Sept 30, 2017 Should No Longer Be Relied Upon‍​

* RXI - ON MARCH 20, DETERMINED INTERIM FINANCIAL STATEMENTS FOR QTRS ENDED MARCH 31, JUNE 30, AND SEPT 30, 2017 SHOULD NO LONGER BE RELIED UPON‍​

Mar 26 2018

BRIEF-RXi Pharmaceuticals Qtrly Loss Per Share $0.84

* RXI PHARMACEUTICALS REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS AND RECENT CORPORATE HIGHLIGHTS

Mar 26 2018

Earnings vs. Estimates